Skip to main
CAMP

CAMP Stock Forecast & Price Target

CAMP Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Camp4 Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development of regulatory RNA-based therapeutics for the treatment of genetic diseases of the central nervous system and liver. Their pipeline products have shown promising preclinical data, demonstrating the ability to restore protein levels and reverse motor, memory, and hyperactivity/anxiety deficits. Additionally, the company's collaboration with GSK provides a strong validation of its ASO therapy platform. With the potential for significant market demand and a diverse pipeline, Camp4 Therapeutics has a positive outlook for future growth and success.

Bears say

Camp4 Therapeutics is a clinical-stage biopharmaceutical company that develops regulatory RNA-based therapeutics to treat genetic diseases of the central nervous system and liver. Despite the upcoming milestone for CMP-002, there are significant risks that could impact the company's financial performance and valuation, such as the uncertainty surrounding the success of its early-stage development programs and potential competition from larger companies with more resources. Additionally, accurate valuation is complex, and the current price may not fully reflect these risks.

CAMP has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CAMP4 Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CAMP4 Therapeutics Corp (CAMP) Forecast

Analysts have given CAMP a Buy based on their latest research and market trends.

According to 6 analysts, CAMP has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CAMP4 Therapeutics Corp (CAMP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.